Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative
- Lewis Cantley, Ph.D. Named 2020 Award Winner for the Discovery of PI3K Enzyme and its Role in Wide Range of Diseases from Diabetes to Cancer
Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. The round was led by Fund+, with the participation, next to V-Bio Ventures, of VIB, UCB Ventures, SFPI-FPIM, and several Belgian family offices. ExeVir Bio has been established by Belgian partners combining world class science, antibody engineering, manufacturing, blue-chip venture capital investment and Flemish Government financing, which have joined forces in a unique collaboration to boost the development of new therapies to combat Covid-19.
Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has been acquired by Boehringer Ingelheim. The acquisition follows two years of successful cooperation. Research and production will continue in Anacura’s labs, close to Ghent, Belgium. The current management and staff will play a crucial role in the implementation and further development of stem cell technology within Boehringer Ingelheim.
Biotech is booming in Belgium. To support the evolving needs of this world-class ecosystem, the Mariën family initiated and are realizing Obelisc: a new and additional Bio-accelerator in Ghent’s science park. The building will service the larger start-ups graduating from local bio-incubators as well as international companies looking to put down roots in Belgian soil.
Since VIB was established, the world class research institute has been led by a duo of managing directors. As Johan Cardoen recently stepped down for health reasons, Jérôme Van Biervliet has been chosen for the position alongside Jo Bury. We sat down with both Jérôme Van Biervliet and Jo Bury to hear their thoughts on VIB’s vital role in the ever-evolving Belgian biotech ecosystem.
Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The epidemic has been fueled by widespread abuse of prescription opioids and a dramatic increase in the availability of illicit opioids such as heroin. In this article, we examine some steps to overcoming this issue and improving the way we treat pain.
A new mechanism causing colorectal cancer has been discovered by researchers from VIB and Ghent University. A specific protein was found to affect the integrity of the intestinal wall, allowing infiltrating bacteria to cause inflammation that drives cancer progression. Promisingly, the scientists also demonstrated that manipulating the immune system or microbiome can prevent this chain event, findings that may lead to new treatments for colorectal cancer.
In a recent article, we discussed how the most prescribed drugs are usually indicated for common noncommunicable diseases. These include chronic conditions like diabetes, heart disease, GERD and mental health issues. Regarding treatment innovation, these prevalent diseases are often underserved when compared to less common, but more profitable, orphan diseases. In this article, we look at some of the underlying factors causing these noncommunicable diseases and what could be done to prevent them.
Johnson & Johnson Celebrates Role of Scientists In Society with 2020 Dr. Paul Janssen Award for Biomedical Research, Part of the Champions of Science® Initiative
- Lewis Cantley, Ph.D. Named 2020 Award Winner for the Discovery of PI3K Enzyme and its Role in Wide Range of Diseases from Diabetes to Cancer
Ghent, Belgium, 28 July 2020 – Today V-Bio Ventures announces its investment in a EUR 23 million Series A financing into ExeVir Bio. The round was led by Fund+, with the participation, next to V-Bio Ventures, of VIB, UCB Ventures, SFPI-FPIM, and several Belgian family offices. ExeVir Bio has been established by Belgian partners combining world class science, antibody engineering, manufacturing, blue-chip venture capital investment and Flemish Government financing, which have joined forces in a unique collaboration to boost the development of new therapies to combat Covid-19.
Ghent, Belgium, 27 July 2020 – GST, the stem cell specialist for horses and pets within the Anacura Group, has been acquired by Boehringer Ingelheim. The acquisition follows two years of successful cooperation. Research and production will continue in Anacura’s labs, close to Ghent, Belgium. The current management and staff will play a crucial role in the implementation and further development of stem cell technology within Boehringer Ingelheim.
Biotech is booming in Belgium. To support the evolving needs of this world-class ecosystem, the Mariën family initiated and are realizing Obelisc: a new and additional Bio-accelerator in Ghent’s science park. The building will service the larger start-ups graduating from local bio-incubators as well as international companies looking to put down roots in Belgian soil.
Since VIB was established, the world class research institute has been led by a duo of managing directors. As Johan Cardoen recently stepped down for health reasons, Jérôme Van Biervliet has been chosen for the position alongside Jo Bury. We sat down with both Jérôme Van Biervliet and Jo Bury to hear their thoughts on VIB’s vital role in the ever-evolving Belgian biotech ecosystem.
Opioid misuse is a public health crisis that has resulted in debilitation, deaths, and significant social and economic impact. The epidemic has been fueled by widespread abuse of prescription opioids and a dramatic increase in the availability of illicit opioids such as heroin. In this article, we examine some steps to overcoming this issue and improving the way we treat pain.
A new mechanism causing colorectal cancer has been discovered by researchers from VIB and Ghent University. A specific protein was found to affect the integrity of the intestinal wall, allowing infiltrating bacteria to cause inflammation that drives cancer progression. Promisingly, the scientists also demonstrated that manipulating the immune system or microbiome can prevent this chain event, findings that may lead to new treatments for colorectal cancer.
In a recent article, we discussed how the most prescribed drugs are usually indicated for common noncommunicable diseases. These include chronic conditions like diabetes, heart disease, GERD and mental health issues. Regarding treatment innovation, these prevalent diseases are often underserved when compared to less common, but more profitable, orphan diseases. In this article, we look at some of the underlying factors causing these noncommunicable diseases and what could be done to prevent them.